In this article (Clin Cancer Res 2016;22:1095–102), which was published in the March 1, 2016, issue of Clinical Cancer Research (1), the corresponding author informed us of a labeling error in Fig. 1D in the published article. This figure depicts the relationship between pMAPKAP-K2 percent inhibition from baseline and ralimetinib plasma concentration at matching time points. The figure legend and associated text refer to the data as being from “cycle 1 day 1.” However, the current plot is actually pharmacokinetic/pharmacodynamic data from “cycle 1 day 14.”

On page 1098, the legend for Fig. 1D should read as follows:

  • D, the relationship between pMAPKAP-K2 percent inhibition from baseline and ralimetinib plasma concentration at matching time points following the cycle 1 day 14. Error bars represent SD.

On page 1100, the paragraph under the “Pharmacodynamics” heading in the Results section should read as follows:

  • The primary pharmacodynamic biomarker in this study was pMAPKAP-K2. Figure 1D illustrates the relationship between pMAPKAP-K2 percent inhibition from baseline and ralimetinib plasma concentration at matching time points following the cycle 1 day 14 dose. In general, there was a reciprocal relationship between ralimetinib plasma concentration and pMAPKAPK-2 inhibition. At the dose of 300 mg in Part C and in Part D, the average pMAPKAPK-2 inhibition reached above 50% on day 1.

The conclusions put forth in this article remain unchanged. The authors regret this error.

1.
Patnaik
A
,
Haluska
P
,
Tolcher
AW
,
Erlichman
C
,
Papadopoulos
KP
,
Lensing
JL
, et al
A first-in-human phase I study of the oral p38 MAPK inhibitor, ralimetinib (LY2228820 Dimesylate), in patients with advanced cancer
.
Clin Cancer Res
2016
;
22
:
1095
102
.